Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

80.61 +1.44 (+1.82%)
Streaming Delayed Price Updated: 9:52 AM EDT, Sep 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies
From Gilead Sciences, Inc.
Via Business Wire
Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Announces Second Quarter 2024 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
From Gilead Sciences, Inc.
Via Business Wire
Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
From Gilead Sciences, Inc.
Via Business Wire
Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024
From Gilead Sciences, Inc.
Via Business Wire
Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia
From Gilead Sciences, Inc.
Via Business Wire
Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025
From Gilead Sciences, Inc.
Via Business Wire
Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024
From Gilead Sciences, Inc.
Via Business Wire
Positive News is Driving This Cancer Drug Maker’s Stock Higher
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather 
Via MarketBeat
MarketBeat Week in Review – 6/17 - 6/21
Markets were calmer this week, with the Dow index posting the biggest gains, but it's too early to tell if this is the start of a broader market rally 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
Gilead Sciences Stock Surges on HIV Treatment Trial Success
Gilead Sciences (NASDAQ: GILD) saw its stock jump nearly 10% yesterday after announcing groundbreaking results from its HIV treatment trial. 
Via MarketBeat
Exposures Product Safety
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END 
Via FinancialNewsMedia
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
From FN Media Group LLC
Via GlobeNewswire
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment
From Gilead Sciences, Inc.
Via Business Wire
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA
From Gilead Sciences, Inc.
Via Business Wire
Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
From Gilead Sciences, Inc.
Via Business Wire
Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
From Gilead Sciences, Inc.
Via Business Wire
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
From Gilead Sciences, Inc.
Via Business Wire
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024
From Gilead Sciences, Inc.
Via Business Wire
Gilead Provides Update on Phase 3 TROPiCS-04 Study
From Gilead Sciences, Inc.
Via Business Wire
Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
From Gilead Sciences, Inc.
Via Business Wire
The P3 App: Empowering and Elevating Underprivileged Youth from Socioeconomically Disadvantaged Areas Through Innovative Mentorship
CHICAGO - May 18, 2024 - PRLog -- The Pulse of Perseverance alongside Gilead is proud to announce the launch of the P3 mobile app, a pioneering platform unveiled at our signature benefit event on May... 
Via PRLog
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.